Circulating tumor DNA (ctDNA) are small pieces of DNA from cancer cells that are released into the blood. ctDNA can be detected with a blood test, also called a liquid biopsy.
In a recent post, we shared guidelines stating the lack of evidence to use ctDNA testing to guide MBC treatment decisions. However, new information suggests that ctDNA may be used in some people to determine eligibility for specific drugs. ctDNA testing continues to be an active area of MBC research and clinical trials.
This information may be useful to help start a conversation with your doctor about whether ctDNA testing may be right for you.
Introduction to ctDNA and Liquid Biopsies
- MedLine Plus: What is ctDNA and How is it Used to Manage Cancer?
- Research Advocacy Network: Liquid Biopsy Tutorial
ctDNA in MBC
- Healio: Liquid Biopsy in MBC
- OncLive (Article and Video): Applications of ctDNA Assessment in MBC
- Targeted Oncology: ctDNA Informs Targeted Therapy Choice for MBC
- National Institutes of Health Journal Article and Simple Summary: Role of ctDNA in Breast Cancer
ctDNA in HR+ MBC
- Cancer Network: ctDNA in HR+ MBC
- US Food and Drug Administration: Alpelisib and ctDNA Test for MBC
- US Food and Drug Administration: Elacestrant and ctDNA Test for MBC
ctDNA in HER2+ MBC
- National Institutes of Health Journal Article and Simple Summary: The Potential of Liquid Biopsy in HER2-Positive MBC
ctDNA in HER2- MBC
- OncLive: National Comprehensive Cancer Network Adds Neratinib to New MBC Guidelines
- Oncology Nursing News: National Comprehensive Cancer Network Guidelines Now Include Neratinib For MBC
ctDNA in Triple-Negative MBC
- Healio: Liquid Biopsy Predictive of Survival in Triple-Negative MBC
- Cancer Therapy Advisor: ctDNA Surveillance Proves Challenging in Triple-Negative Breast Cancer
MBC Clinical Trials
- Metastatic Trial Search: Trials for ctDNA
Last Modified on March 31, 2023